Cameron S McAlpine, PhD
img_Cameron S Mcalpine
ASSISTANT PROFESSOR | Medicine, Cardiology
Research Topics
Alzheimer's Disease, Atherosclerosis, Brain, Cardiovascular, Hematopoiesis, Immunology, Inflammation, Macrophage, Sleep Medicine
Multi-Disciplinary Training Area
Immunology [IMM], Neuroscience [NEU]
Project 1. Brain-body circuits connect sleep and cardiovascular disease
Sleep is critical to health, and we should be asleep for a third of our life. Despite its importance more than a third of adults do not get sufficient sleep. We study the bidirectional brain-body circuits that connect sleep and cardiovascular health. We have shown that sleep fragmentation activates hematopoiesis in the bone marrow leading to an oversupply of circulating immune cells which aggravates atherosclerosis (Nature, 2019). We identified a neuro-immune axis linking the brain’s hypothalamus to the control of immune growth factors in the bone marrow. We have also shown that sleep mediates the heterogeneity of hematopoietic stem cells, their epigenetic programming, and the emergence of clonal hematopoiesis (Cell, 2021, J.Ex.Med 2022). Moving forward, we are exploring the many complex pathways and systems that link sleep to immune cell biology and cardiovascular health.
Research in the McAlpine lab
The McAlpine lab investigates immune networks in sleep, cardiovascular disease, and Alzheimer's disease. Please visit the McAlpine lab website:
Project 2. Immune growth factors in glial-peripheral immune crosstalk
The immune system plays an important role in the pathophysiology of neurodegenerative diseases like Alzheimer’s disease and multiple sclerosis. We pursue research exploring the role of immune growth factors in regulating glial-peripheral immune cell interactions in neurodegenerative diseases. We have uncovered how the growth factor interleukin-3 (IL-3) coordinates glial-peripheral immune communication and the function of myeloid cells in the brain during Alzheimer's disease (Nature 2021) and multiple sclerosis (Immunity 2023).

BSc, Acadia University

PhD, McMaster University

Postdoctoral Fellowship, Massachusetts General Hospital and Harvard Medical School

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. McAlpine did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.